Staff Profile

PhD Vacancies - We are always pleased to receive informal enquires from prospective PhD students. Please feel free to email me f you are interested - lisa.russell@ncl.ac.uk

Current Position

March 2022 - present - Senior Lecturer in Childhood Cancer and Haematology, Newcastle University

Themes

Primary - Chromosome Biology and Cell Cycle

Secondary - Precision Medicine, Genetics and Informatics

Tertiary - Applied Cancer Therapeutics and Outcomes 

Area of expertise

Haemato-oncology

Genetics

Leukaemia

Qualifications

2022: Senior Lectureship - open-ended

2020: Lectureship - open-ended

2015: Newcastle University Research Fellow

2015: John Goldman Fellow

2011: KKLF Intermediate Fellowship

2007: PhD Cancer Sciences Division, University of Southampton

2002: BSc Biology, University of Southampton

Previous positions

Aug 2020 - Mar 2022: Lecturer in Haemato-Oncology, Newcastle University

Aug 2015-July 2020: Newcastle University Research Fellow, Newcastle University

June 2015-June 2018: John Goldman Fellow, Leuka, Newcastle University

Feb 2001-Aug 2015: Kay Kendall Leukaemia Fund Intermediate Research Fellow, Newcastle University

April 2008- Feb 2011: Research Associate, Newcastle University

December 2006-March 2008: Postdoctoral Scientist, University of Southamtpon

April 2008-January 2011: Research Associate, Newcastle University

Professional Awards

FASEB Hematological Malignancies Abstract Award 2021

British Society of Haematology Travel Grant to attend the EMBO B-cell development and Leukemia meeting (2019)

British Society of Haematology Travel Grant to attend the 57^th ASH annual Meeting (2015)

British Society of Haematology Travel Grant to attend the FASEB summer conference on Hematological malignancies (2011)

British Society of Haematology Travel Grant to attend the 50^th ASH Annual Meeting (2008)

European Haematology Association Travel Grant (2008)

Wessex Medical Research Prize for Postgraduate Research in Biomedical Sciences (2008)

Poster prize at the Cancer Sciences Conference, University of Southampton (2007)

Oral presentation prize at the British Society of Haematology (2007)

Invited Presentations

2nd annual meeting of the European Society for Paediatric Oncology, May 2021

University of Southampton - Seminar at the Centre for Cancer Immunology Feb 2019

Leuka Seminar and Reception September 2018

29th Annual Meeting of the International BFM Study Group, Helsinki, Finland, May 2018 

Association of Clinical Genetic Science (ACGS) Annual Meeting – Cancer Genetics, September 2015

24th Annual Meeting of the International BFM Study Group, Kiel, Germany, May 2013

BSHG, Warwick University, September 2011

Professor Nick Cross, Wessex Regional Genetics Laboratory, Salisbury, 15th June 2011

Professor Mel Greaves and Dr Lyndal Kearny, Institute of Cancer Research, 15th April 2009

Memberships

British Society of Haematology since 2008

European Haematology Association since 2020

Manuscript/Grant Peer Review

Journals: Blood, British Journal of Haematology, Leukemia, Clinical Epigenetics and Haematologica.

Funding bodies: MRC, Cure Kids, Wellcome Trust Indian Alliance Fellowship Scheme.

Boards and Committees

Scientific lead for Childhood Leukaemia Research UK.

Editorial Board Member for Scientific Reports, a journal from Nature Publishing Group since February 2015.

Co-lead for the Newcastle University Centre for Cancer Fellowship and Grants Committee

Early career researcher lead for the Chromosome Biology and Cell Cycle theme

Research Interests

The characterisation of genomic abnormalities that drive the development of haematological malignancies has progressed significantly over the past 40 years. One major advance has been the link between genetic abnormalities and outcome. My research has provided two such examples highlighting that rearrangements involving the immunoglobulin loci (Ig) and the cytokine receptor CRLF2 are associated with a poor outcome. These findings have led to treatment changes within the United States and are currently being used to inform the next paediatric and adult ALL treatment trials within the UK.

I am known within the field of leukaemia research for characterising novel and recurrent translocations involving the Ig loci. My future research goals are to increase the molecular and understanding of both CRLF2 and Ig driven malignancies.

Due to the heterogeneity of Ig rearrangements in haematological malignancies, I wish to pursue a challenging programme of research which aims to exploit a common mechanism driving the cancer, to provide a unified treatment option for this disparate group of diseases. With over 7,200 patients (23% of all haematological malignancies) diagnosed with an Ig rearranged malignancy each year in the UK, targeting the molecular switch which allows these rearrangements to overexpress oncogenes, could provide common mechanisms to exploit therapeutically to increase the cure rates for this poor prognostic subtype.

Staff Supervision

Group Leader: Dr Lisa Russell

Nefeli Karataraki - Senior Research Technician

Daniel Kent - PhD student

Jessica Saville - PhD student 

Letizia Marchetti - Research Assistant

Phoebe Snow - Research Assistant

Public Engagement

I have been a STEM (Science, Technology, Electronics and Mathematics) Ambassador since 2009. 

I have been involved in running open days for the general public and charity fundraisers.

Current and Past Funding

We gratefully acknowledge financial support from:

The Wellcome Trust

MRC

Leukaemia UK (previously Leuka)

Kidscan

Newcastle upon Tyne Hospitals NHS Foundation Trust

JGW Patterson Foundation

Blood Cancer UK (previously Bloodwise)

Kay Kendall Leukaemia Fund

CCLG Little Princess Trust

CCLG Ruby's Fund

Student Supervision

PhD: Dino Masic (PhD 2016), Kent Fung (PhD 2022), Jessica Saville (PhD 2018 – 2022), Dan Kent (PhD 2019 – 2023)

MPhil:  Brynelle Myers (MPhil 2017)

MRes: Supervised master’s students between 2009-2021

BSc: Supervised undergraduate students (Biomedical Sciences) between 2009-2021

Lecturing/Seminars

MMS8101: Medical Research in the 21st Century, 2018/2019

MMB8008: Chromosome Biology and Cell Cycle Control in Health and Disease, 2021 - present

MMB8007: Cancer Studies, 2021 - present

BSc Pharmacology - Anticancer Therapy, 2020 - present

BMS3025 Bioinformatics, 2020 - present

PGR poster presentation seminar and one-one feedback sessions, 2019 - present

• Belhocine M, Simonin M, Abad-Flores JD, Cieslak A, Manosalva I, Pradel L, Smith C, Mathieu EL, Charbonnier G, Martens JHA, Stunnenberg HG, Maqbool MA, Mikulasova A, Russell LJ, Rico D, Puthier D, Ferrier P, Asnafi V, Spicuglia S. Dynamics of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes. Genome Research 2022, 32(7), 1328-1342.
• Mikulasova A, Kent D, Trevisan-Herraz M, Karataraki N, Fung KTM, Ashby C, Cieslak A, Yaccoby S, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Morgan GJ, Asnafi V, Spicuglia S, Brackley CA, Corcoran AE, Hambleton S, Walker BA, Rico D, Russell LJ. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research 2022, epub ahead or print.
• Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, Wilson A, Nizami S, Nakjang S, Zhou P, Schwab C, Sinclair P, Russell LJ, Coxhead J, Halsey C, Allan JM, Harrison CJ, Moorman AV, Heidenreich O, Vormoor J. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine 2022, 3(8), 100717.
• Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung K, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, Cazzaniga G, Gohring G, de Groot-Kruseman H, Haferlach C, Lo Nigro L, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, van der Velden V, Rand V, Hunger SP, Harrison CJ, Bacon C, van Delft F, Loh M, Moppett J, Vormoor J, Walker B, Moorman AV, Russell L. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematologica 2022, epub ahead of pub.
• Potter N, Jones L, Blair H, Strehl S, Harrison CJ, Greaves M, Kearney L, Russell LJ. Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. Leukemia 2019, 33, 893-904.
• Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
• Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2016, 56(5), 363-372.
• Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood 2016, 127(16), 1998-2006.
• Schwab C, Enshaei A, Roberts KG, Russell LJ, Harvey RC, Chen IM, Willman CL, Mullighan C, Vora AJ, Moorman AV, Harrison CH. The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003. In: American Society of Hematology (ASH). 2016, San Diego, CA, USA: American Society of Hematology.
• Wade MA, Sunter NJ, Fordham SE, Long A, Masic D, Russell J, Harrison CJ, Rand V, Elstob C, Bown N, Rowe D, Lowe C, Cuthbert G, Bennett S, Crosier S, Bacon CM, Onel K, Scott K, Scott D, Travis LB, May FEB, Allan JM. c-MYC is a radiosensitive locus in human breast cells. Oncogene 2015, 34, 4985-4994.
• Yousafzai YM, Williams MTS, Bhatti S, Cousins A, Rehe K, Bomken S, Sinclair P, Weston VJ, Russell LJ, Heidenreich O, Irving JAE, Vormoor J, Graham GJ, Halsey C. Childhood pre-B acute lymphoblastic leukaemia cells capable of central nervous system engraftment are common, heterogeneous and transit the blood-cerebrospinal fluid barrier. In: 55th Annual Scientific Meeting of the British Society for Haematology. 2015, Edinburgh, UK: Wiley.
• Russell LR, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
• Russell LJ, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
• Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
• Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
• Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia 2015, 29(8), 1623-1631.
• Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, Laczko KS, Fielding AK, Goldstone AH, Goulden N, Mitchell CD, Wade R, Vora A, Moorman AV, Harrison CJ. IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology 2014, 32(14), 1453-1462.
• Jeffries SJ, Jones L, Harrison CJ, Russell LJ. IGH@ Translocations Co-exist With Other Primary Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia. Haematologica 2014, 99(8), 1334-1342.
• Chapiro E, Radford-Weiss I, Cung H-A, Dastugue N, Nadal N, Taviaux S, Baring C, Struski S, Talmant P, Vandenberghei P, Mozziconacci M-J, Tigaud I, Lefebvre C, Penther D, Bastard C, Lippert E, Mugneret F, Romana S, Bernard OA, Harrison CJ, Russell LJ, Nguyen-Khaca F. Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genetics 2013, 206(5), 162-173.
• Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica 2013, 98(7), 1081-1088.
• van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VHJ, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Khankahdani LM, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013, 122(15), 2622-2629.
• O'Reilly J, Russell LJ, Cooney J, Ensor HM, Purtill D, Wright M, Moorman AV. Unravelling the prognostic effect of IKZF1 deletions and IGH@-CRLF2 in adult acute lymphoblastic leukaemia. Pathology 2013, 45(6), 609-612.
• Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ Translocations, CRLF2 Deregulation and Microdeletions in Adolescents and Adults with Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2012, 30(25), 3100-3108.
• Schwab C, Chilton L, Enshaie A, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Vora AJ, Mitchell CD, Richards SM, Goulden N, Kinsey S, Moorman AV, Harrison CJ. Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL). In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Schwab C, Chilton L, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL) Are Associated with Major Cytogenetic Subgroups. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Russell LJ, Jones L, Erhorn A, Ensahei A, Masic D, Bentley H, Laczko KS, Harrison CJ. Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Van Der Veer A, Waanders E, Pieters R, Willemse ME, Reijmersdaal S, Russell LJ, Harrison CJ, Evans WE, van der Velden VHJ, Hoogerbrugge PM, van Leeuwen FN, Escherich G, Horstman M, Khankandani LM, Rizopoulos D, de Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26(10), 2204-2211.
• Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S, Krentz S, Cario G, Kasper D, Schmitt K, Russell LJ, Potschger U, Stanulla M, Eckert C, Mann G, Haas OA, Panzer-Grumayer R. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood 2012, 120(26), 5134-5142.
• Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Potschger U, Harrison CJ, Stanulla M, Panzer-Grumayer R, Haas OA, Moorman AV, Assoc Italiana Ematologia Oncologi, Natl Canc Res Inst NCRI-Childrens. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology 2012, 158(6), 772-777.
• Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7), 2129-2136.
• Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman A, Strefford J, Harrison CJ. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011, 117(25), 6848-6855.
• Chapiro E, Russell LJ, Struski S, Cave H, Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA, Harrison CJ, Nguyen-Khac F. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010, 24(7), 1362-1364.
• Chapiro E, Russell L, Lainey E, Kaltenbach S, Ragu C, Della-Valle V, Hanssens K, Macintyre EA, Radford-Weiss I, Delabesse E, Cave H, Mercher T, Harrison CJ, Nguyen-Khac F, Dubreuil P, Bernard OA. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24(3), 642-645.
• Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, Kronnie GT, Bourquin JP, Domany E, Izraeli S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115(5), 1006-1017.
• Russell LJ, DeCastro DG, Griffiths M, Telford N, Bernard O, Panzer-Gruemayer R, Heidenreich O, Moorman AV, Harrison CJ. A novel translocation, t(14;19)(q32;p13) involving IGHalpha and the cytokine receptor for erythropoietin. Leukemia 2009, 23, 614-617.
• Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving JAE, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab CJ, Tonnies H, Dyer MJ, Siebert R, Harrison CJ. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114(13), 2688-2698.
• Rand V, Parker H, Russell LJ, Irving J, Jones L, Masic D, Minto L, Morrison H, Robinson H, Schwab C, Sinclair P, Moorman AV, Strefford JC, Harrison CJ. What Is the Initiating Mechanism of iAMP21 in Childhood B Cell Precursor ALL?. In: Blood: 51st Annual Meeting of the American Society of Hematology. 2009, New Orleans, LA: American Society of Hematology.
• Russell L, Harrison CJ. IDENTIFICATION OF MULTIPLE NOVEL IGH@ TRANSLOCATIONS IN ADOLESCENT ACUTE LYMPHOBLASTIC LEUKAEMIA. Haematologica: the hematology journal 2008, 93(S1), 197-198.
• Russell LJ, Capasso M, Vater I, Moorman AV, Akasaka T, Harder L, Heidenreich O, Machado L, Gest S, Strefford JC, Chandrasekaran T, Tonnies H, Majid A, Bernard O, Dyer MJS, Siebert R, Harrison CJ. IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
• Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Karran EL, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJS, Harrison C. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111(1), 387-391.
• Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R, Karran EL, Brown DG, Cain K, Harder L, Gesk S, Martin-Subero JI, Atherton MG, Brüggemann M, Calasanz MJ, Davies T, Haas OA, Hagemeijer A, Kempski H, Lessard M, Lillington DM, Moore S, Nguyen-Khac F, Radford-Weiss I, Schoch C, Struski S, Talley P, Welham MJ, Worley H, Strefford JC, Harrison CJ, Siebert R, Dyer MJS. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007, 109(8), 3451-361.
• Chapiro E, Russell LJ, Radford-Weiss I, Bastard C, Lessard M, Struski S, Cave H, Fert-Ferrer S, Barin C, Maarek O, Della-Valle V, Strefford JC, Berger R, Harrison CJ, Bernard OA, Nguyen-Khac F. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 2006, 108(10), 3560-3563.